Prefer Newsweek on Google to see more of our trusted coverage when you search. In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes ...
Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech ...
Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...
The promise of a better pan-RAS inhibitor Erasca has been described as the poor man’s Revolution Medicines. Impoverished ...
This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts. Listen ...
The Fight of Our Lives highlights biotech’s impact on patient lives in both the short- and long-term, urging continued ...
Slow rolling chaos at the FDA and its effects on drug approvals. How to think about risk when investing in biotech. A review of results from DNA researcher Twist Bioscience. Don't wait! Be sure to get ...
Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 by 9 percentage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results